alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[115th Congress Public Law 314]
[From the U.S. Government Publishing Office]

[[Page 132 STAT. 4431]]

Public Law 115-314
115th Congress

                                 An Act

 
To designate the facility of the United States Postal Service located at 
   105 Duff Street in Macon, Missouri, as the ``Arla W. Harrell Post 
             Office''. <<NOTE: Dec. 13, 2018 -  [S. 3442]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. ARLA W. HARRELL POST OFFICE.

    (a) Designation.--The facility of the United States Postal Service 
located at 105 Duff Street in Macon, Missouri, shall be known and 
designated as the ``Arla W. Harrell Post Office''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Arla W. 
Harrell Post Office''.

    Approved December 13, 2018.

LEGISLATIVE HISTORY--S. 3442:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 164 (2018):
            Nov. 15, considered and passed Senate.
            Nov. 29, considered and passed House.

                                  <all>
```
FROM:                                        FOR:
Swenson/Falker Associates Inc.               CNS, Inc.
1111 TCF Tower, 121 S. 8th Street            1250 Park Rd.
Minneapolis, Minn. 55402                     Chanhassen, Minn. 55417
Contact - Curt Swenson 612/371-0000          Contact - Richard E. Jahnke or
                                                       Daniel E. Cohen
                                                       612/474-7600

FOR IMMEDIATE RELEASE


CNS, INC., RECEIVES OFFICIAL NOTICE OF PATENT
ALLOWANCE FOR BREATHE RIGHT DEVICE

     MINNEAPOLIS, Nov. 9 -- CNS, Inc., (NASDAQ/NM:CNXS) has received the 
official notice of allowance from the U.S. Patent Office with regard to a 
patent based on the original application for its Breathe Right(R) nasal
strips. The company had said on Monday that it expected to receive the notice
soon.

     "The patent, when issued, will provide our Breathe Right product with the
significant protection we have always expected it would receive," said Daniel
E. Cohen, M.D., chairman and chief executive officer of CNS.

     CNS, based in Minneapolis, designs, manufactures and markets consumer
products, including the Breathe Right nasal strip. The Breathe Right strip
improves breathing by reducing nasal airflow resistance and can be 
effective in eliminating or reducing snoring.

                                     # # #

11/09/95
<TABLE> <S> <C>

 <ARTICLE>                                                          5
 <LEGEND>
This schedule contains summary financial information extracted from the
Consolidated Balance Sheets (Unaudited) as of July 30, 2000 and October 31, 1999
and the Consolidated Statements of Operations (Unaudited) for the quarters ended
July 30, 2000 and August 1, 1999.
 </LEGEND>
 <MULTIPLIER>                  1,000
 <CURRENCY>                    U.S. DOLLARS

<S>                                                       <C>
 <PERIOD-TYPE>                                                  3-MOS
 <FISCAL-YEAR-END>                                        OCT-31-1999
 <PERIOD-START>                                           MAY-01-2000
 <PERIOD-END>                                             JUL-30-2000
 <EXCHANGE-RATE>                                                    1
 <CASH>                                                        36,819
 <SECURITIES>                                                       0
 <RECEIVABLES>                                                247,426
 <ALLOWANCES>                                                  35,511
 <INVENTORY>                                                   50,967
 <CURRENT-ASSETS>                                             328,620
 <PP&E>                                                       219,283
 <DEPRECIATION>                                               143,256
 <TOTAL-ASSETS>                                               413,448
 <CURRENT-LIABILITIES>                                        149,207
 <BONDS>                                                            0
 <PREFERRED-MANDATORY>                                              0
 <PREFERRED>                                                        0
 <COMMON>                                                         217
 <OTHER-SE>                                                   (82,721)
 <TOTAL-LIABILITY-AND-EQUITY>                                 413,448
 <SALES>                                                      377,462
 <TOTAL-REVENUES>                                             377,462
 <CGS>                                                        366,023
 <TOTAL-COSTS>                                                366,023
 <OTHER-EXPENSES>                                               7,547
 <LOSS-PROVISION>                                                   0
 <INTEREST-EXPENSE>                                             2,073
 <INCOME-PRETAX>                                              (72,912)
 <INCOME-TAX>                                                    (136)
 <INCOME-CONTINUING>                                          (72,776)
 <DISCONTINUED>                                                     0
 <EXTRAORDINARY>                                                    0
 <CHANGES>                                                          0
 <NET-INCOME>                                                 (72,776)
 <EPS-BASIC>                                                    (3.35)
 <EPS-DILUTED>                                                  (3.35)


</TABLE>
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1065 Linoleic acid. ( a ) Linoleic acid ((Z, Z)-9, 12-octadecadienoic acid (C17H31COOH) (CAS Reg. No. 60-33-3)), a straight chain unsaturated fatty acid with a molecular weight of 280.5, is a colorless oil at room temperature. Linoleic acid may be prepared from edible fats and oils by various methods including hydrolysis and saponification, the Twitchell method, low pressure splitting with catalyst, continuous high pressure counter current splitting, and medium pressure autoclave splitting with catalyst.
( b ) The ingredient must be of a purity suitable for its intended use. The ingredient must also meet the specifications in § 172.860(b) of this chapter.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter and as a nutrient supplement as defined in § 170.3(o)(20) of this chapter.
( 2 ) The ingredient is used in foods at levels not to exceed current good manufacturing practice. The ingredient may be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the act) or with regulations promulgated under section 412(a)(2) of the act.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[49 FR 48534, Dec. 13, 1984, as amended at 73 FR 8606, Feb. 14, 2008]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.2875 Differential pressure transducer. ( a ) *Identification.* A differential pressure transducer is a two-chambered device intended for medical purposes that is often used during pulmonary function testing. It generates an electrical signal for subsequent display or processing that is proportional to the difference in gas pressures in the two chambers.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1119, Jan. 16, 1996; 66 FR 38794, July 25, 2001]
#### § 810.18 Public notice.

The agency will make available to the public in the weekly FDA Enforcement Report a descriptive listing of each new mandatory recall issued under § 810.13. The agency will delay public notification of orders when the agency determines that such notification may cause unnecessary and harmful anxiety in individuals and that initial consultation between individuals and their health professionals is essential.
# C_2016016EN.01003001.xml

| 18.1.2016 | EN | Official Journal of the European Union | C 16/30 |
| --- | --- | --- | --- |

18.1.2016

EN

Official Journal of the European Union

C 16/30

---

Judgment of the General Court of 24 November 2015 — Netherlands v Commission

(Case T-126/14) (1)

1

((EAGGF - Guarantee Section - EAGF and EAFRD - Financial correction applied in respect of the non-reporting of interest - Obligation to state reasons - Obligation to account for interest - Article 32(5) of Regulation (EC) No 1290/2005 - Principle of equivalence - Obligation of due diligence))

(2016/C 016/36)

Language of the case: Dutch

Parties

Parties

Applicant: Kingdom of the Netherlands (represented by: M. K. Bulterman, J. Langer and M. Noort, acting as Agents)

Applicant:

Defendant: European Commission (represented by: H. Kranenborg and P. Rossi, acting as Agents)

Defendant:

Re:

Re:

Application for partial annulment of Commission Implementing Decision 2013/763/EU of 12 December 2013 on excluding from European Union financing certain expenditure incurred by the Member States under the Guarantee Section of the European Agricultural Guidance and Guarantee Fund (EAGGF), under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) (OJ 2013 L 338, p. 81).

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls Commission Implementing Decision 2013/763/EU of 12 December 2013 on excluding from European Union financing certain expenditure incurred by the Member States under the Guarantee Section of the European Agricultural Guidance and Guarantee Fund (EAGGF), under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) in so far as it applied to the Kingdom of the Netherlands a financial correction amounting to EUR 4 703 231,78 in respect of the non-reporting of interest on claims relating to the late payment of additional levies before 1 April 1993 and on export refunds wrongly paid before 1 April 1995; |
| --- | --- |

1.

Annuls Commission Implementing Decision 2013/763/EU of 12 December 2013 on excluding from European Union financing certain expenditure incurred by the Member States under the Guarantee Section of the European Agricultural Guidance and Guarantee Fund (EAGGF), under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) in so far as it applied to the Kingdom of the Netherlands a financial correction amounting to EUR 4 703 231,78 in respect of the non-reporting of interest on claims relating to the late payment of additional levies before 1 April 1993 and on export refunds wrongly paid before 1 April 1995;

| 2. | Orders the European Commission to bear its own costs and to pay those incurred by the Kingdom of the Netherlands. |
| --- | --- |

2.

Orders the European Commission to bear its own costs and to pay those incurred by the Kingdom of the Netherlands.

---

(1)  OJ C 112, 14.4.2014.

1

---
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3050 Beta-glucan serological assays. ( a ) *Identification.* Beta-glucan serological assays are devices that consist of antigens or proteases used in serological assays. The device is intended for use for the presumptive diagnosis of fungal infection. The assay is indicated for use in patients with symptoms of, or medical conditions predisposing the patient to invasive fungal infection. The device can be used as an aid in the diagnosis of deep seated mycoses and fungemias.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Serological Assays for the Detection of Beta-Glucan.” See § 866.1(e) for the availability of this guidance document.
[69 FR 56936, Sept. 23, 2004]
# C_2016118EN.01002501.xml

| 4.4.2016 | EN | Official Journal of the European Union | C 118/25 |
| --- | --- | --- | --- |

4.4.2016

EN

Official Journal of the European Union

C 118/25

---

Judgment of the General Court of 26 February 2016 — Bodson and Others v EIB

(Case T-241/14 P) (1)

1

((Appeal - Civil service - EIB staff - Contractual nature of the employment relationship - Remuneration - Reform of the EIB rewards scheme - Obligation to state reasons - Distortion - Errors of law))

(2016/C 118/26)

Language of the case: French

Parties

Parties

Appellants: Jean-Pierre Bodson (Luxembourg, Luxembourg), Dalila Bundy (Cosnes-et-Romain, France), Didier Dulieu (Roussy-le-Village, France), Marie-Christel Heger (Nospelt, Luxembourg), Evangelos Kourgias (Senningerberg, Luxembourg), Manuel Sutil (Luxembourg), Patrick Vanhoudt (Gonderange, Luxembourg) and Henry von Blumenthal (Bergem, Luxembourg) (represented by: L. Levi, lawyer)

Appellants:

Other party to the proceedings: European Investment Bank (represented by: C. Gómez de la Cruz, T. Gilliams and G. Nuvoli, acting as Agents, and by P.-E. Partsch, lawyer)

Other party to the proceedings:

Re:

Re:

Appeal brought against the judgment of the European Union Civil Service Tribunal (Third Chamber) of 12 February 2014 in Bodson and Others v EIB (F-83/12, ECR-SC, EU:F:2014:15) seeking annulment of that judgment.

Bodson and Others

EIB

Operative part of the judgment

Operative part of the judgment

The Court:

| 1) | Dismisses the action; |
| --- | --- |

1)

Dismisses the action;

| 2) | Orders Mr Bodson and the other applicants whose names are listed in the Annex to bear their own costs and those incurred by the European Investment Bank (EIB) in the present proceedings. |
| --- | --- |

2)

Orders Mr Bodson and the other applicants whose names are listed in the Annex to bear their own costs and those incurred by the European Investment Bank (EIB) in the present proceedings.

---

(1)  OJ C 223, 14.7.2014.

1

---
MICHAEL EDWARD 

HOWARTH,

Petitioner,

v.

JULIE L. JONES, Secretary, 

Florida Department of Corrections,

Respondent.

___________________________/

IN THE DISTRICT COURT OF APPEAL

FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO 

FILE MOTION FOR REHEARING AND 

DISPOSITION THEREOF IF FILED

CASE NO. 1D15-1698

Opinion filed May 5, 2015.

Petition for Writ of Habeas Corpus -- Original Jurisdiction.

Michael Edward Howarth, pro se, Petitioner.

Jennifer Parker, General Counsel, and Susan A. Maher, Assistant General Counsel, 

Department of Corrections, Tallahassee, for Respondent.

PER CURIAM.

DISMISSED.

WOLF, ROWE, and SWANSON, JJ., CONCUR.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the Balance
Sheet and the Statements of Revenue and Expenses and is qualified in its
entirety by reference to such Report on Form 10-Q.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       1,697,487
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               1,832,662
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   1,824,414
<TOTAL-LIABILITY-AND-EQUITY>                 1,832,662
<SALES>                                              0
<TOTAL-REVENUES>                               424,061
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                60,821
<LOSS-PROVISION>                               (8,240)
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (213,860)
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
§ 830.130 Suspension or revocation of the accreditation of an issuing agency. FDA may suspend or revoke the accreditation of an issuing agency if FDA finds, after providing the issuing agency with notice and opportunity for an informal hearing in accordance with part 16 of this chapter, that the issuing agency or any officer, employee, or other agent of the issuing agency: ( a ) Has been guilty of misrepresentation or failure to disclose required information in obtaining accreditation;
( b ) Has failed to fulfill the responsibilities outlined in § 830.120;
( c ) Has failed to protect against conflicts of interest that may impede the issuing agency's ability to independently operate a fair and neutral identifier system;
( d ) In the operation of the issuing agency, has engaged in any anticompetitive activity to restrain trade; or
( e ) Has violated or aided and abetted in the violation of any regulation issued under section 510(e) or section 519(f) of the Federal Food, Drug, and Cosmetic Act.
UN PUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 23

- 6308

CHARLIE L. HARDIN

,

Plaintiff

- Appellant

,

v.

MAGISTRATE JUDGE ELIZABETH JOI PEAKE; KATY POOLE, SUPERINTENDENT OF SCOTLAND; OFFICER WILEY; QUEEN GERALD; CAPTAIN COVINGTON; MUNGO; OFFICER ADAMS; OFFICER BEATHE; OFFICER NEAL; HARRISON; OFFICER DOUGLAS; OFFICER WHITE;

SGT. LOCKLEAR; SGT. PIERCE

,

Defendants

- Appellees

.

Appeal from the United States District Court for the Middle District of North Carolina

, at
Greensboro

. Joe L. Webster, Magistrate Judge. ( 1:22

- cv

- 00691

- WO

- JLW )

Submitted : May 18, 2023 Decided: May 23, 2023

Before NIEMEYER, RICHARDSON, and RUSHING, Circuit Judges.

Dismissed by un published per curiam opinion

.

Charlie L. Hardin , Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit. USCA4 Appeal: 23-6308 Doc: 9 Filed: 05/23/2023 Pg: 1 of 22 PER CURIAM:

Charlie L. Hardin seeks to appeal the magistrate judge’s report recommending that

the district court dismiss his civil action under 28 U.S.C. § 1915A(b). * This court may

exercise jurisdiction only over final orders, 28 U.S.C. § 1291, and certain interlocutory and

collateral orders, 28 U.S.C. § 1292; Fed. R. Ci v. P. 54(b); Cohen v. Beneficial Indus. Loan

Corp. , 337 U.S. 541, 545

- 4 7 (1949). The report Hardin seeks to appeal is neither a final

order nor an appealable interlocutory or collateral order. Accordingly, we dismiss the

appeal for lack of jurisdiction. We deny Hardin’s motion to appoint counsel and dispense

with oral argument because the facts and legal contentions are adequately presented in the

materials before this court and argument would not aid the decisional process.

DISMISSED

* The magistrate judge issued both an order granting Hardin in forma pauperis status and a report recommending that the district court dismiss his civil action. Hardin’s appeal does not pertain to the order granting him in forma pauperis status. USCA4 Appeal: 23-6308 Doc: 9 Filed: 05/23/2023 Pg: 2 of 2
#### Milton J. Lurie et al. *v.*Board of Zoning Appeals of the City of New Haven et al.

*Richard Belford,*for the appellees (plaintiffs).

*Edward B. Winnick,*for the appellants (defendant Ezekiel at al.).

Argued November 5

decided November 6, 1968

The motion by the plaintiffs to dismiss the appeal from the Court of Common Pleas in New Haven County is granted.
I 

118TH CONGRESS 

2D SESSION H. R. 7798 

To amend the Plant Protection Act to establish a fund for spotted wing 

drosophila research and mitigation, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 22, 2024 

Mrs. CHAVEZ-DEREMER (for herself, Ms. SLOTKIN, Mr. VALADAO, and Ms. 

SALINAS) introduced the following bill; which was referred to the Committee on Agriculture 

A BILL 

To amend the Plant Protection Act to establish a fund 

for spotted wing drosophila research and mitigation, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Spotted Wing Abate5 ment Trust Act of 2024’’ or the ‘‘ SWAT Act of 2024’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds that— 

8 (1) the spotted wing drosophila, an invasive 

9 species from East Asia, has caused significant damVerDate Sep 11 2014 01:06 Apr 10, 2024 Jkt 049200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H7798.IH H7798

dmwilson on DSKJM0X7X2PROD with BILLS
2 

•HR 7798 IH

1 age to many valuable fruit crops in the United 

2 States, including raspberries, blackberries, blue3 berries, strawberries, peaches, plums, and cherries; 

4 and 

5 (2) the Department of Agriculture estimates 

6 that spotted wing drosophila account for a combined 

7 20 percent revenue loss across strawberry, blueberry, 

8 raspberry, blackberry, and cherry crops, based on re9 ported yield losses due to that species. 

10 SEC. 3. SPOTTED WING DROSOPHILA RESEARCH AND MITI11 GATION. 

12 Subtitle A of the Plant Protection Act (7 U.S.C. 

13 7711 et seq.) is amended by adding at the end the fol14 lowing: 

15 ‘‘SEC. 420A. SPOTTED WING DROSOPHILA RESEARCH AND 

16 MITIGATION. 

17 ‘‘(a) IN GENERAL.—The Administrator of the Ani18 mal and Plant Health Inspection Service (referred to in 

19 this section as the ‘Administrator’) shall establish a fund 

20 within the Department of Agriculture to fund research re21 lating to, and activities to mitigate the negative effects of 

22 spotted wing drosophila. 

23 ‘‘(b) ADMINISTRATION OF FUND.—The Adminis24 trator shall— 


dmwilson on DSKJM0X7X2PROD with BILLS
3 

•HR 7798 IH

1 ‘‘(1) determine eligible recipients to enter into 

2 cooperative agreements with, or award grants to, 

3 using amounts in the fund established under sub4 section (a); and 

5 ‘‘(2) oversee the activities carried out using 

6 amounts in that fund. 

7 ‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 

8 is authorized to be appropriated for the fund established 

9 under subsection (a) $6,500,000 for the fiscal year in 

10 which the Spotted Wing Abatement Trust Act of 2024 is 

11 enacted and each of the 4 fiscal years thereafter.’’. 

Æ 


dmwilson on DSKJM0X7X2PROD with BILLS